Neumora Therapeutics, Inc.
corporate_fare Company Profile
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for NMRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for NMRA spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Neumora 10-Q Confirms Going-Concern Doubt on $85.7M Cash
- Neumora Q3: $85.7M Cash, No Runway Guidance, NMRA-215 IND Filed
- Neumora Posts $34.4M Q3 Loss, $85.7M Cash, Skips Runway Guidance
- Neumora Gets Nasdaq Bid-Price Deficiency Notice, 180 Days to Reach $1.00
- Neumora Flags Going Concern Doubt as Cash Runs Short
Financial Snapshot
Short Interest & Short Volume
5.12 days to coverFINRA reported short interest of 7,006,355 shares in NMRA as of the October 30, 2026 settlement, a 24.2% increase from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 73.4% of NMRA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.